Edwards Lifesciences (EW) Capital Expenditures (2009 - 2026)

Edwards Lifesciences' Capital Expenditures history runs 18 years deep, the most recent figure standing at $64.9 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 15.89% year-over-year to $64.9 million in Q1 2026; TTM through Mar 2026 was $269.1 million, a 10.7% increase from a year earlier, with the FY2025 full-year figure at $260.2 million, up 3.09% from the prior year.
• Capital Expenditures retreated to $64.9 million in Q1 2026 per EW's latest filing, from $97.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $97.4 million in Q4 2025 and bottomed at $43.1 million in Q2 2022.
• The 5-year median for Capital Expenditures is $59.9 million (2022), against an average of $63.2 million.
• Across the five-year window, Capital Expenditures tumbled 43.6% in 2024 and surged 95.58% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $68.9 million in 2022, then grew by 28.16% to $88.3 million in 2023, then tumbled by 43.6% to $49.8 million in 2024, then jumped by 95.58% to $97.4 million in 2025, then slumped by 33.37% to $64.9 million in 2026.
• Per Business Quant, the three latest EW Capital Expenditures figures stand at $64.9 million (Q1 2026), $97.4 million (Q4 2025), and $57.5 million (Q3 2025).